EP4384201A4 - Verfahren zur reduzierung der produktion von iga, igm und/oder igg mittels sbcma-varianten und fc-fusionsproteinen davon - Google Patents

Verfahren zur reduzierung der produktion von iga, igm und/oder igg mittels sbcma-varianten und fc-fusionsproteinen davon

Info

Publication number
EP4384201A4
EP4384201A4 EP22856825.9A EP22856825A EP4384201A4 EP 4384201 A4 EP4384201 A4 EP 4384201A4 EP 22856825 A EP22856825 A EP 22856825A EP 4384201 A4 EP4384201 A4 EP 4384201A4
Authority
EP
European Patent Office
Prior art keywords
sbcma
iga
igm
igg
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22856825.9A
Other languages
English (en)
French (fr)
Other versions
EP4384201A2 (de
Inventor
Amato J Giaccia
Yu Miao
Xin Eric Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akso Biopharmaceutical Inc
Original Assignee
Akso Biopharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akso Biopharmaceutical Inc filed Critical Akso Biopharmaceutical Inc
Publication of EP4384201A2 publication Critical patent/EP4384201A2/de
Publication of EP4384201A4 publication Critical patent/EP4384201A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22856825.9A 2021-08-11 2022-08-11 Verfahren zur reduzierung der produktion von iga, igm und/oder igg mittels sbcma-varianten und fc-fusionsproteinen davon Pending EP4384201A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163232124P 2021-08-11 2021-08-11
PCT/US2022/074868 WO2023019223A2 (en) 2021-08-11 2022-08-11 METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Publications (2)

Publication Number Publication Date
EP4384201A2 EP4384201A2 (de) 2024-06-19
EP4384201A4 true EP4384201A4 (de) 2025-07-30

Family

ID=85200996

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22856825.9A Pending EP4384201A4 (de) 2021-08-11 2022-08-11 Verfahren zur reduzierung der produktion von iga, igm und/oder igg mittels sbcma-varianten und fc-fusionsproteinen davon

Country Status (7)

Country Link
EP (1) EP4384201A4 (de)
JP (1) JP2024529128A (de)
KR (1) KR20240053675A (de)
CN (1) CN118678963A (de)
AU (1) AU2022327178A1 (de)
CA (1) CA3228678A1 (de)
WO (1) WO2023019223A2 (de)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040716A2 (en) * 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
AU2005200008A1 (en) * 1999-01-07 2005-01-27 Zymogenetics, Inc. Soluble receptor BR43x2 and methods of using
WO2008119042A2 (en) * 2007-03-27 2008-10-02 Zymogenetics, Inc. Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
US20110110943A1 (en) * 1999-01-07 2011-05-12 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
EP4146683A1 (de) * 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April- und baff-hemmende immunmodulatorische proteine und verfahren zur verwendung davon
EP4196164A1 (de) * 2020-08-12 2023-06-21 The Board of Trustees of the Leland Stanford Junior University Sbcma-varianten und fc-fusionsproteine davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9812634A (pt) 1997-09-12 2000-08-22 Biogen Inc April - uma proteìna com efeitos de crescimento
EP1028306B1 (de) 1998-08-28 2008-10-15 Mitutoyo Corporation Verfahren und vorrichtung für analyse und für die generation eines programms zur messung von koordinaten und oberflächeneigenschaften
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
RU2006117324A (ru) * 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
US20220235360A1 (en) * 2019-06-04 2022-07-28 Inserm (Institut National De La Santé Et De La Recherche Médecale) Methods for modulating immunoglobulin expression

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040716A2 (en) * 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
AU2005200008A1 (en) * 1999-01-07 2005-01-27 Zymogenetics, Inc. Soluble receptor BR43x2 and methods of using
US20110110943A1 (en) * 1999-01-07 2011-05-12 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using
WO2008119042A2 (en) * 2007-03-27 2008-10-02 Zymogenetics, Inc. Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
EP4146683A1 (de) * 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April- und baff-hemmende immunmodulatorische proteine und verfahren zur verwendung davon
EP4196164A1 (de) * 2020-08-12 2023-06-21 The Board of Trustees of the Leland Stanford Junior University Sbcma-varianten und fc-fusionsproteine davon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023019223A2 *

Also Published As

Publication number Publication date
AU2022327178A1 (en) 2024-03-28
WO2023019223A3 (en) 2023-09-28
CN118678963A (zh) 2024-09-20
WO2023019223A2 (en) 2023-02-16
KR20240053675A (ko) 2024-04-24
EP4384201A2 (de) 2024-06-19
JP2024529128A (ja) 2024-08-01
CA3228678A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
DK4232463T3 (da) Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses
EP3714319C0 (de) System und verfahren zur verwendung von blickverfolgung und brennpunktverfolgung
EP3612930C0 (de) System und verfahren zur implementierung verschiedener typen von blockchain-verträgen
EP4030897A4 (de) T-zell-modulierende polypeptide und verfahren zur verwendung davon
EP3565828A4 (de) Sirp1-alpha-41bbl-fusionsprotein und verfahren zur verwendung davon
EP4408897A4 (de) Antigenbindende polypeptide, antigenbindende polypeptidkomplexe und verfahren zur verwendung davon
EP4021498A4 (de) Artenübergreifende anti-latente tgf-beta-1-antikörper und verfahren zur verwendung
DK4073098T5 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
EP3935086A4 (de) Für cd93 spezifische, therapeutisches antigen bindende proteine und verfahren zur verwendung davon
EP4181995A4 (de) System und verfahren zur konzentration von gas
EP3857860C0 (de) System und verfahren zur disambiguierung von internet-of-things-vorrichtungen
EP4100433A4 (de) Verfahren zur herstellung und/oder anreicherung von rekombinanten antigen-bindenden molekülen
EP4061848A4 (de) Anti-ror-2-antikörper und verfahren zur verwendung
EP4031188A4 (de) Radiomarkierung von anti-cd45 immunoglobulin und verfahren zur verwendung davon
EP4401764A4 (de) Anti-siglec-6-antikörper und verfahren zur verwendung davon
EP4055535A4 (de) System und verfahren zur authentifizierung von handtaschen
EP4006667A4 (de) System und verfahren zur erzeugung von nc-programmen
EP3870193C0 (de) System und verfahren zur bestimmung der deamidierung und immunogenizität von polypeptiden
EP4449030C0 (de) Verfahren zur vermessung von heliostaten und verfahren zur kalibrierung von heliostaten
EP4007606A4 (de) Verfahren zur verabreichung von anti-siglec-8-antikörpern und corticosteroiden
EP4579453A4 (de) Verfahren, system und knoten zur erzeugung von behältern
EP3946471C0 (de) Poröse hohlfasermembran und verfahren zur verwendung davon zur auswahl von immuncheckpoint-inhibitor
EP4086783A4 (de) Verfahren und system zur erzeugung elektronischer horizonte
EP4326780A4 (de) Anti-gpc3-antikörper, multispezifische antikörper und verfahren zur verwendung
EP3920956A4 (de) Verfahren zur verwendung von glykosylierten therapeutischen proteinen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240301

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111707

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20250702

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101AFI20250626BHEP

Ipc: A61P 37/06 20060101ALI20250626BHEP

Ipc: C07K 14/715 20060101ALI20250626BHEP

Ipc: C07K 16/46 20060101ALI20250626BHEP

Ipc: C07K 19/00 20060101ALI20250626BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN